Day: March 25, 2024

ARMOUR Residential REIT, Inc. Announces Guidance for April 2024 Dividend Rate Per Common Share

Written by Customer Service on March 25, 2024. Posted in Dividend Reports And Estimates.

VERO BEACH, Florida, March 25, 2024 (GLOBE NEWSWIRE) — ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) (“ARMOUR” or the “Company”) today announced guidance on the April 2024 cash dividend for the Company’s Common Stock of $0.24 per Common share. April 2024 Common Stock Dividend InformationMonth Dividend Holder of Record Date Payment DateApril 2024 $0.24 April 15, 2024 April 29, 2024Certain Tax MattersARMOUR has elected to be taxed as a real estate investment trust (“REIT”) for U.S. Federal income tax purposes. In order to maintain this tax status, ARMOUR is required to timely distribute substantially all of its ordinary REIT taxable income. Dividends paid in excess of current tax earnings and profits for the year will generally not be taxable to common stockholders. Actual dividends are determined...

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

Written by Customer Service on March 25, 2024. Posted in Earnings Releases And Operating Results.

Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH)Completed enrollment in the Phase 2b portion and enrolled first patient into the Phase 3 portion of the IMPAHCT trial of AV-101 in November 2023Expanded intellectual property portfolio with two issued patents in 2023Board of Directors expanded in 2023 with the addition of Donald Santel and Habib Dable, each a former CEO with PAH experience and significant product approval and launch expertiseCash runway into 2026, based on our current operating planWALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients...

Nilam Resources Enters Letters of Intent to Acquire 24,800 Bitcoin

Written by Customer Service on March 25, 2024. Posted in Mergers And Acquisitions.

SNOHOMISH, Wash., March 25, 2024 (GLOBE NEWSWIRE) — via IBN – Nilam Resources, Inc. (OTC PINK: NILA) today announced that it has entered into a Letter of Intent (LOI) with Xyberdata Ltd to acquire 100% of the common stock of a special purpose entity, to be established under the name MindWave that will hold 24,800 Bitcoin. Nilam Resources, Inc., will issue a newly authorized Preferred Class of Series C Stock in in exchange for 24,800 Bitcoins at a discounted rate relative to current market prices. Nilam Resources, Inc. will acquire 100% of the capital stock of MindWave, a special purpose entity in Mauritius, which will hold digital assets including 24,800 Bitcoins and other assets. These assets will serve as collateral to raise capital for investment in high yield generating projects. The acquisition marks a significant strategic...

TMC Announces Fourth Quarter and Full Year 2023 Results

Written by Customer Service on March 25, 2024. Posted in Earnings Releases And Operating Results.

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) — TMC the metals company Inc. (Nasdaq: TMC) (“TMC” or “the Company”), an explorer of lower-impact battery metals from seafloor polymetallic nodules, today provided a corporate update and fourth quarter and full year financial results for the period ending December 31, 2023. Q4 2023 and FY 2023 Financial Highlights$15.2 million cash used in operations for the quarter ended December 31, 2023 Net loss of $33.5 million and net loss per share of $0.11 for the quarter ended December 31, 2023 For the full year 2023, a net loss of $73.8 million or $0.26 per share (compared to $171 million and $0.71 per share in 2022) Total cash on hand of approximately $6.8 million at December 31, 2023, excluding $9 million received in January 2024 as final payment from the Registered Direct Offering announced...

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Written by Customer Service on March 25, 2024. Posted in Earnings Releases And Operating Results.

Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024 Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients Received U.S. FDA Fast Track designation for zotatifin in combination with fulvestrant and abemaciclib for treatment of ER+/HER2- advanced metastatic breast cancer Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH, Calif. and REDWOOD CITY, Calif., March 25, 2024 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs)...

Madison Metals Closes First Tranche of Non-Brokered Private Placement

Written by Customer Service on March 25, 2024. Posted in Public Companies.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, March 25, 2024 (GLOBE NEWSWIRE) — Madison Metals Inc. (“Madison” or the “Company”) (CSE: GREN) (OTCQB: MMTLF) (FSE: 4EF0) is pleased to announce that, further to its press release dated March 12, 2024, it has issued 3,069,600 units (the “Units”) at a price of CDN$0.35 per unit for aggregate gross proceeds of CDN$1,074,360 in connection with the first tranche of a private placement (the “Private Placement”). Each Unit consists of one (1) common share (a “Common Share”) and one-half (1/2) common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each full Warrant entitles the holder thereof to purchase one Common Share in the capital of the Company for a price of CDN$0.50 for a period of eighteen (18) months...

Income Financial Trust Financial Results to December 31, 2023

Written by Customer Service on March 25, 2024. Posted in Public Companies.

TORONTO, March 25, 2024 (GLOBE NEWSWIRE) — Income Financial Trust (“Income Financial”) announces that its annual financial statements and management report of fund performance for the year ended December 31, 2023 are now available at www.sedarplus.com and Income Financial’s website at www.quadravest.com. For further information, please contact Investor Relations at 416-304-4443, toll free at 1-877-4-Quadra (1-877-478-2372), or visit www.quadravest.com.

Provident Financial Services, Inc. Receives FDIC and New Jersey Department of Banking and Insurance Approvals for its Merger with Lakeland Bancorp, Inc.

Written by Customer Service on March 25, 2024. Posted in Mergers And Acquisitions.

ISELIN, N.J. and OAK RIDGE, N.J., March 25, 2024 (GLOBE NEWSWIRE) — Provident Financial Services, Inc. (NYSE:PFS) (“Provident”), the parent company of Provident Bank, and Lakeland Bancorp, Inc. (Nasdaq: LBAI) (“Lakeland”), the parent company of Lakeland Bank, today announced receipt of regulatory approvals from the Federal Deposit Insurance Corporation and the New Jersey Department of Banking and Insurance for Provident and Lakeland to complete their previously announced merger. With these approvals, the only pending regulatory approval required to complete the merger is the approval of the Board of Governors of the Federal Reserve System. Upon completion of the merger, the combined company will operate under the Provident name and will benefit from enhanced scale, and opportunities for growth and profitability. Provident’s and...

Provident Financial Services, Inc. Receives FDIC and New Jersey Department of Banking and Insurance Approvals for its Merger with Lakeland Bancorp, Inc.

Written by Customer Service on March 25, 2024. Posted in Mergers And Acquisitions.

Quadient – Solid FY 2023 results bring the Back to Growth strategic plan to a close with Quadient well positioned for long-term profitable growth

Written by Customer Service on March 25, 2024. Posted in Earnings Releases And Operating Results.

Solid FY 2023 results bring the Back to Growth strategic plan to a close with Quadient well positioned for long-term profitable growth Key highlightsFY 2023 consolidated sales of €1,062 million, up +1.9% organically(1) FY 2023 subscription-related revenue up +3.4% on an organic basis, representing 70% of total revenue Strong performance from North America with all three solutions contributing to the +4.5% organic growth in the region in FY 2023. North America represents 57% of Group Sales FY 2023 current EBIT(2) of €157 million, up 9.3% organically driven by both software and locker profitability improvement Net attributable income of €69 million, up from €13 million in FY 2022 Proposed dividend of €0.65 per share, up for the third consecutive year, and up +8% year-over-year Leverage ratio excluding leasing at 1.65x3 exceeding the...

Day: March 25, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice